vs
CrossAmerica Partners LP（CAPL）与Steris（STE）财务数据对比。点击上方公司名可切换其他公司
Steris的季度营收约是CrossAmerica Partners LP的1.7倍（$1.5B vs $866.3M），Steris净利率更高（12.9% vs 1.2%，领先11.7%），Steris同比增速更快（9.2% vs -8.3%），Steris自由现金流更多（$199.5M vs $22.4M），过去两年Steris的营收复合增速更高（15.8% vs -4.1%）
塔峰资本合伙人（TowerBrook Capital Partners）是一家总部位于伦敦和纽约的投资管理公司，2005年从索罗斯基金管理分拆独立。该机构主打私募股权及结构性机会投资，曾收购奢侈品品牌Jimmy Choo控股权，截至2025年其管理规模超250亿美元，官网公示在管投资项目共110个。
Steris plc是一家美爱合资的医疗设备企业，专注于为美国医疗体系提供灭菌服务及外科手术相关产品。其实际运营总部位于美国俄亥俄州门托市，深耕医疗消毒、感染防控、手术耗材等领域，为医疗机构提供专业可靠的医疗解决方案。
CAPL vs STE — 直观对比
营收规模更大
STE
是对方的1.7倍
$866.3M
营收增速更快
STE
高出17.4%
-8.3%
净利率更高
STE
高出11.7%
1.2%
自由现金流更多
STE
多$177.1M
$22.4M
两年增速更快
STE
近两年复合增速
-4.1%
损益表 — Q4 FY2025 vs Q3 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $866.3M | $1.5B |
| 净利润 | $10.2M | $192.9M |
| 毛利率 | 12.4% | 43.8% |
| 营业利润率 | 3.0% | 18.3% |
| 净利率 | 1.2% | 12.9% |
| 营收同比 | -8.3% | 9.2% |
| 净利润同比 | -39.6% | 11.2% |
| 每股收益（稀释后） | $0.24 | $1.96 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收CAPLSTE
| Q4 25 | $866.3M | $1.5B | ||
| Q3 25 | $971.8M | $1.5B | ||
| Q2 25 | $961.9M | $1.4B | ||
| Q1 25 | $862.5M | $1.5B | ||
| Q4 24 | $944.2M | $1.4B | ||
| Q3 24 | $1.1B | $1.3B | ||
| Q2 24 | $1.1B | $1.3B | ||
| Q1 24 | $941.5M | $1.1B |
净利润CAPLSTE
| Q4 25 | $10.2M | $192.9M | ||
| Q3 25 | $13.6M | $191.9M | ||
| Q2 25 | $25.2M | $177.4M | ||
| Q1 25 | $-7.1M | $145.7M | ||
| Q4 24 | $16.9M | $173.5M | ||
| Q3 24 | $10.7M | $150.0M | ||
| Q2 24 | $12.4M | $145.4M | ||
| Q1 24 | $-17.5M | $-1.4M |
毛利率CAPLSTE
| Q4 25 | 12.4% | 43.8% | ||
| Q3 25 | 10.8% | 44.2% | ||
| Q2 25 | 10.5% | 45.1% | ||
| Q1 25 | 10.4% | 43.3% | ||
| Q4 24 | 10.7% | 44.5% | ||
| Q3 24 | 10.3% | 43.6% | ||
| Q2 24 | 9.2% | 44.7% | ||
| Q1 24 | 8.6% | 40.2% |
营业利润率CAPLSTE
| Q4 25 | 3.0% | 18.3% | ||
| Q3 25 | 2.9% | 18.2% | ||
| Q2 25 | 4.3% | 17.7% | ||
| Q1 25 | 0.2% | 14.6% | ||
| Q4 24 | 3.0% | 17.9% | ||
| Q3 24 | 2.5% | 16.5% | ||
| Q2 24 | 2.5% | 14.5% | ||
| Q1 24 | -1.4% | 22.0% |
净利率CAPLSTE
| Q4 25 | 1.2% | 12.9% | ||
| Q3 25 | 1.4% | 13.1% | ||
| Q2 25 | 2.6% | 12.8% | ||
| Q1 25 | -0.8% | 9.8% | ||
| Q4 24 | 1.8% | 12.7% | ||
| Q3 24 | 1.0% | 11.3% | ||
| Q2 24 | 1.1% | 11.4% | ||
| Q1 24 | -1.9% | -0.1% |
每股收益（稀释后）CAPLSTE
| Q4 25 | $0.24 | $1.96 | ||
| Q3 25 | $0.34 | $1.94 | ||
| Q2 25 | $0.64 | $1.79 | ||
| Q1 25 | $-0.20 | $1.48 | ||
| Q4 24 | $0.42 | $1.75 | ||
| Q3 24 | $0.27 | $1.51 | ||
| Q2 24 | $0.31 | $1.46 | ||
| Q1 24 | $-0.48 | $-0.02 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $3.1M | $423.7M |
| 总债务越低越好 | $687.2M | $1.9B |
| 股东权益账面价值 | — | $7.2B |
| 总资产 | $964.7M | $10.6B |
| 负债/权益比越低杠杆越低 | — | 0.27× |
8季度趋势，按日历期对齐
现金及短期投资CAPLSTE
| Q4 25 | $3.1M | $423.7M | ||
| Q3 25 | $5.8M | $319.2M | ||
| Q2 25 | $9.7M | $279.7M | ||
| Q1 25 | $6.7M | $171.7M | ||
| Q4 24 | $3.4M | $155.2M | ||
| Q3 24 | $7.8M | $172.2M | ||
| Q2 24 | $5.5M | $198.3M | ||
| Q1 24 | $6.3M | $207.0M |
总债务CAPLSTE
| Q4 25 | $687.2M | $1.9B | ||
| Q3 25 | $700.8M | $1.9B | ||
| Q2 25 | $722.7M | $1.9B | ||
| Q1 25 | $774.1M | $1.9B | ||
| Q4 24 | $763.9M | $2.0B | ||
| Q3 24 | $769.2M | $2.2B | ||
| Q2 24 | $786.7M | $2.2B | ||
| Q1 24 | $795.8M | $3.1B |
股东权益CAPLSTE
| Q4 25 | — | $7.2B | ||
| Q3 25 | — | $7.0B | ||
| Q2 25 | — | $7.0B | ||
| Q1 25 | — | $6.6B | ||
| Q4 24 | — | $6.4B | ||
| Q3 24 | — | $6.6B | ||
| Q2 24 | — | $6.4B | ||
| Q1 24 | — | $6.3B |
总资产CAPLSTE
| Q4 25 | $964.7M | $10.6B | ||
| Q3 25 | $998.9M | $10.4B | ||
| Q2 25 | $1.0B | $10.4B | ||
| Q1 25 | $1.1B | $10.1B | ||
| Q4 24 | $1.1B | $10.0B | ||
| Q3 24 | $1.1B | $10.2B | ||
| Q2 24 | $1.2B | $10.1B | ||
| Q1 24 | $1.2B | $11.1B |
负债/权益比CAPLSTE
| Q4 25 | — | 0.27× | ||
| Q3 25 | — | 0.27× | ||
| Q2 25 | — | 0.27× | ||
| Q1 25 | — | 0.29× | ||
| Q4 24 | — | 0.32× | ||
| Q3 24 | — | 0.33× | ||
| Q2 24 | — | 0.35× | ||
| Q1 24 | — | 0.50× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $29.4M | $298.2M |
| 自由现金流经营现金流 - 资本支出 | $22.4M | $199.5M |
| 自由现金流率自由现金流/营收 | 2.6% | 13.3% |
| 资本支出强度资本支出/营收 | 0.8% | 6.6% |
| 现金转化率经营现金流/净利润 | 2.89× | 1.55× |
| 过去12个月自由现金流最近4个季度 | $55.8M | $917.1M |
8季度趋势，按日历期对齐
经营现金流CAPLSTE
| Q4 25 | $29.4M | $298.2M | ||
| Q3 25 | $24.4M | $287.8M | ||
| Q2 25 | $22.6M | $420.0M | ||
| Q1 25 | $15.0M | $260.8M | ||
| Q4 24 | $11.1M | $332.8M | ||
| Q3 24 | $41.9M | $250.7M | ||
| Q2 24 | $28.9M | $303.7M | ||
| Q1 24 | $5.8M | $254.8M |
自由现金流CAPLSTE
| Q4 25 | $22.4M | $199.5M | ||
| Q3 25 | $17.7M | $201.3M | ||
| Q2 25 | $10.8M | $326.4M | ||
| Q1 25 | $4.9M | $189.9M | ||
| Q4 24 | $3.9M | $243.6M | ||
| Q3 24 | $34.2M | $148.8M | ||
| Q2 24 | $23.6M | $195.7M | ||
| Q1 24 | $-289.0K | $163.3M |
自由现金流率CAPLSTE
| Q4 25 | 2.6% | 13.3% | ||
| Q3 25 | 1.8% | 13.8% | ||
| Q2 25 | 1.1% | 23.5% | ||
| Q1 25 | 0.6% | 12.8% | ||
| Q4 24 | 0.4% | 17.8% | ||
| Q3 24 | 3.2% | 11.2% | ||
| Q2 24 | 2.1% | 15.3% | ||
| Q1 24 | -0.0% | 14.6% |
资本支出强度CAPLSTE
| Q4 25 | 0.8% | 6.6% | ||
| Q3 25 | 0.7% | 5.9% | ||
| Q2 25 | 1.2% | 6.7% | ||
| Q1 25 | 1.2% | 4.8% | ||
| Q4 24 | 0.8% | 6.5% | ||
| Q3 24 | 0.7% | 7.7% | ||
| Q2 24 | 0.5% | 8.4% | ||
| Q1 24 | 0.6% | 8.2% |
现金转化率CAPLSTE
| Q4 25 | 2.89× | 1.55× | ||
| Q3 25 | 1.79× | 1.50× | ||
| Q2 25 | 0.90× | 2.37× | ||
| Q1 25 | — | 1.79× | ||
| Q4 24 | 0.66× | 1.92× | ||
| Q3 24 | 3.92× | 1.67× | ||
| Q2 24 | 2.33× | 2.09× | ||
| Q1 24 | — | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
CAPL
| Retail Segment | $505.3M | 58% |
| Wholesale | $360.9M | 42% |
| Other | $1.2M | 0% |
STE
| Servicerevenues | $404.7M | 27% |
| Consumablerevenues | $387.1M | 26% |
| Applied Sterilization Technologies | $286.6M | 19% |
| Capitalequipmentrevenues | $272.1M | 18% |
| Life Science | $145.8M | 10% |
